PADI4 and arthritic joint disease: Administration of GSK484 in CIA mice reduces the expression of synovial MPO, NE, and PAD4, decreases NET generation, attenuates arthritis severity, and inhibits macrophage infiltration, supporting its therapeutic potential (167).